Investor Newsletter

Issue 03 2022

MicroPort®



MicroPort® Announces Annual Results for 2021

MicroPort Scientific Corporation (hereafter referred to as "MicroPort®" or the "Group") today announced the annual results of the Company and its subsidiaries for the twelve months ended December 31, 2021 (hereafter referred to as the "Reporting Period").

The Group recorded revenue of US$778.6 million in 2021, representing an increase of 15.0% as compared to 2020. Particularly, the revenue in South America, EMEA (Europe, Middle East and Africa) and North America recorded growth of 29.9%, 16.8% and 6.7% as compared to last year, respectively. Benefited from rapid market penetration and new product launches, the Heart Valve Business, the Neurovascular Devices Business and the Endovascular and Peripheral Vascular Devices Business continued to maintain rapid growth with revenue growth of 93.2%, 72.5% and 45.6%, respectively.

In Cardiovascular Devices Business, the global sales volume of the Group's coronary stents amounted to 1.22 million units, representing an increase of 132.0% as compared to last year, with market share ranking the world's top two and Chinese top one in terms of sales volume.

As for the Orthopedics Devices Business, despite the challenges brought by the complicated development of COVID-19, the international business still achieved a year-on-year revenue growth of 11.8%, and loss reduced sharply by 57.3%.

During the Reporting Period, the CRM Business recorded a revenue of US$220.4 million, representing an increase of 18.8% as compared to last year, among which the international (non-China) CRM Business realized an increase of 17.2% in revenue. During the Reporting Period, the CRM Business in the PRC recorded a revenue of US$13.6 million, representing an increase of 53.7% as compared to last year. Our made-in-China pacemakers have completed over 10,000 implantations accumulatively, further strengthening its leading position with the largest market share among all the domestic players.

Since the beginning of 2021 to date, MicroPort® and associated companies have 22 products obtaining the registration certificates from the NMPA, and 5 products admitted in the Green Path and the Group had a total of 26 products being approved to enter the Green Path, ranking the first in the medical device industry for seven consecutive years. As for the overseas market, the Group also obtained the registration certificates from the United States FDA for 7 products and the CE Markings for 15 products.

MicroPort

Endovastec™ Announces Annual Results for 2021

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (hereafter referred to as "Endovastec™" or the "Group") today announced the annual results of the Company and its subsidiaries for the 12 months ended December 31, 2021 (hereafter referred to as the "Reporting Period"). In the reporting period, the Group recorded revenue of RMB 685 million, representing an increase of 45.59% as compared to the corresponding period of last year, with the net profit RMB 363 million, representing an increase of 45.15%. The net profit attributable to shareholders was RMB 316 million with an increase of 47.17%. The net profit excluding non-recurring gains and losses was RMB 289 million, an increase of 51.08%.

Mr. Qing Zhu, president of Endovastec™, said, “In 2021, the continuing global COVID-19 pandemic, to a certain extent, brought uncertainties to our company's research and development, sales and other work. In the face of the new economic environment, Endovastec™, always driven by innovation, has been improving the portfolios of aortic and peripheral vascular interventional devices with innovative products on the market one after another and key products growing steadily. Meanwhile, we have been accelerating the implementation of the strategy of group-based and global development to continuously expand the domestic and international markets. We had gone through the difficulties in the past year and recorded a new high in sales revenue, delivering a satisfactory performance to our customers, employees and shareholders.”

Mr. Bo Peng, the chief marketing official of MicroPort® and chairman of the Group, said “With the mission of ‘providing trustworthy and universal access to state-of-the-art solutions to endovascular diseases’, Endovastec™ always pay attention to each user's personal feelings, and will continue to invest in product R&D and technology innovation. We will further reduce domestic medical costs in related fields by developing more products with technology and price competitiveness. In addition, we will constantly improve the Group's brand influence in the market to develop Endovastec™ into a globally leading high-tech medical group in the field of aortic and peripheral vascular interventions.”

MicroPort

CardioFlow Medtech
Announces Annual Results for 2021

MicroPort CardioFlow Medtech Corporation (hereafter referred to as the "CardioFlow Medtech" or the "Group") today announced the annual results of the Company and its subsidiaries for the 12 months ended December 31, 2021 (hereafter referred to as the "Reporting Period"). In the Reporting Period, CardioFlow Medtech recorded revenue of RMB200.8 million, representing a year-on-year growth of 93.2%. In addition to the significant growth in revenue, the gross profit margin also improved drastically by 15.4 percentage points to 59.1%.

Mr. Guoming Chen, the president and executive director of the Group, commented, "In 2021, CardioFlow Medtech achieved continuous high growth in revenue and rapid increase in market share benefitting from excellent products portfolio. With years of R&D experience and technological foundation, CardioFlow Medtech has built an integrated platform focusing on the R&D, clinical, manufacturing and commercialization of medical devices for structural heart diseases. In the future, CardioFlow Medtech will continue to maintain the core competitiveness of products, actively expand sales and marketing network, and strive forward to become the leader of total solutions for structural heart diseases."

"The interventional treatment of structural heart diseases in China is still in rapid growth period, there is a large advancement to further expand market penetration and improve innovative technology. In the future, CardioFlow Medtech will make greater breakthrough in market share and product innovation and provide global patients with trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases." said Dr. Luo Qiyi, the chief technology officer of MicroPort®, the non-executive Director and chairman of the Group.

MicroPort® MedBot® Announces Annual Results for 2021

Shanghai MicroPort MedBot (Group) Co., Ltd. (hereafter referred to as "MicroPort® MedBot®"or the “Group”) today announced the annual results of the Company and its subsidiaries for the twelve months ended December 31, 2021 (hereafter referred to as the "Reporting Period"). This is the first annual performance report released by MicroPort® MedBot® since it was successfully listed on the main board of the Hong Kong Stock Exchange on November 2, 2021.

Dr. Chao He, President of MicroPort® MedBot®, commented, “The past 2021 was an important year for MicroPort® MedBot®. With the support and encouragement of people from all walks of life and partners, we achieved the approvals of two core products, Toumai® and DFVision®, and successfully listed the company on the Hong Kong Stock Exchange. In the future, we will remain the faith, forge ahead bravely, continue to explore and innovate, strengthen industrial integration, deepen the cooperation with doctors, and provide all-inclusive solutions for patients and doctors in China even the world.”

Mr. Hongbin Sun, Chief Financial Officer of MicroPort® and Chairman of the Board of MicroPort® MedBot®, stated,“ With the increasing acceptance and popularity of surgical robot technology among doctors and patients, and the improvement of medical infrastructure in China and around the world, we believe the surgical robot market is poised for robust growth. In the future, MicroPort® MedBot® will further strengthen corporate governance, implement active and efficient business strategies, strive to build a global layout of medical robot solution innovation platform, contribute to the high-end medical equipment ‘Made in China’, and better performance to the majority of investors.”

MicroPort® Enrolls First Patient in PROMISE-BIF Study to Investigate the Rapamycin Coronary Balloon Catheter for the Treatment of De Novo Coronary Artery Bifurcation Lesions

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) has announced the enrollment of the first patient in its PROMISE-BIF study, a pre-marketing clinical study of an independently developed coronary rapamycin drug balloon catheter for the treatment of de novo coronary artery bifurcation lesions. The clinical study was initiated by MicroPort® and led by principal investigator Yaling Han.

It is hoped that the PROMISE-BIF research and the subsequent launch of the rapamycin coronary balloon catheter in China will offer real clinical benefit to coronary artery disease patients. MicroPort® remains committed to its brand philosophy "The Patient Always Comes First", and is conducting a number of clinical research programs around the world. These programmes will help MicroPort®'s continuous innovation by providing clinical data to support the expansion of its cardiovascular interventional product portfolio, in turn enabling them to deliver more and improved treatment options for patients with coronary artery disease.





MicroPort® Orthopedics Obtains NMPA Marketing Approval for Two Knee System Products

Suzhou MicroPort Orthopedics Scientific (Group) Co. Ltd. (MicroPort® Orthopedics) recently announced that it has received registration certificates from the National Medical Products Administration (NMPA) for two independently developed knee system products, SoSuperior+™ and MedalOne™, marking the achievement of its knee joint product portfolio in China.

Both approved knee systems inherit the design of MicroPort® Orthopedics' original Medial-Pivot knee system, which has a 20-year track record of clinical effectiveness and the results of 17 years' clinical follow-up data show extraordinarily high prosthesis survival rate (98.8%) and patient satisfaction (95%). The Medial-Pivot knee system requires no intercondylar osteotomy and provides improved joint motion and wear resistance on the basis of maximal bone retention. It helps restore the normal motion mechanics of the knee joint by simulating natural knee motion to maintain stability, resulting in a more natural and flexible postoperative motion mechanics and gait. In 2021, the Advance® Medial-Pivot knee system developed by MicroPort® Orthopedics has received the top rating of "15A" from the Orthopedic Data Evaluation Panel (ODEP), a leading global rating agency of the orthopedic industry, making it the only Chinese company to earn this rating level thus far.

MicroPort

Hyperflex® Balloon Catheter by Endovastec™ Receives Marketing Approval in Japan

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently announced that it has received registration approval from Japan Pharmaceuticals and Medical Devices Agency (PMDA) for its independently-developed Hyperflex® Balloon Catheter (Hyperflex®) as the company's first product approved for marketing in Japan. Hyperflex® obtained CE Mark in 2016 and is already available in overseas markets in South America and Asia.

Mr. Qing Zhu, President of Endovastec™, stated, "The approval of the Hyperflex® Balloon Catheter in Japan signals a growing acceptance of our EVAR devices in more and more national and regional healthcare systems, paving the way for the company's continued marketing in Asia and the globe. Endovastec™ will continue to innovate to improve solutions for aortic diseases and reach more patients worldwide with better products and services."



MicroPort

CardioFlow Medtech Receives Approval for Alwide® Plus Balloon Catheter in Argentina

MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech) recently announced that their Alwide® Plus Balloon Catheter (Alwide® Plus) has received marketing approval from the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).

The successful launch of Alwide® Plus in Argentina marks another strong step forward for CardioFlow Medtech's product line, enabling them to support local TAVI surgeons in handling different surgical challenges. Looking ahead, CardioFlow Medtech will continue to accelerate the commercialization of innovative products and introduce TAVI products to more countries and regions, bringing high-quality, universal total solutions for structural heart disease to more patients around the world.



MicroPort® Lifesciences AutoEx® Chemotherapy Pump Obtains Marketing Approval from NMPA

Shanghai MicroPort Lifesciences Co., Ltd. (MicroPort® Lifesciences) has received marketing approval from China's National Medical Products Administration (NMPA) for its independently-developed new AutoEx® Chemotherapy Infusion Pump (AutoEx®).

Dr. Jia Yao, General Manager of MicroPort® Lifesciences, stated, "AutoEx® is the first chemotherapy infusion pump launched by MicroPort® Lifesciences, and the first approved product in our company's intelligent oncology pain solutions. As we look forward to seeing AutoEx® help more cancer patients regain their health, we at MicroPort® Lifesciences will continue to improve our product portfolio and build a patient management platform focused on microinfusion technology, and provide more patients and doctors with quality and inclusive total medical solutions."



MicroPort



HorizonMedical™'s CryoX™ Vitrification Device Approved for Marketing

Shanghai Horizon Medical Co., Ltd. (HorizonMedical™) has announced that they have obtained medical device registration approval from Zhejiang Provincial Drug Administration for its independently developed CryoX™ Vitrification Device (CryoX™). Suitable for oocytes and embryos vitrification, CryoX™ is HorizonMedical™'s first approved product in the field of cryopreservation for assisted reproduction.

"Vitrification techniques for oocytes and embryos are an essential part of assisted reproduction as they enable future in vitro fertilization or embryo transfer at the appropriate time.", Dr. Guo Zong, General Manager of HorizonMedical™ commented, "Previously, HorizonMedical™ has received market approval for its ovum aspiration needle, embryo transfer catheter and intrauterine insemination catheter. The approval of CryoX™ vitrification device will further expand the company's product line and provide a more comprehensive solution for doctors and families in need. In the future, HorizonMedical™ will accelerate the integration of resources and continue to invest in research and development as well as product innovation to provide more accessible and complete medical solutions for assisted reproduction."

MicroPort

Investor Newsletter

Issue 03 2022

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com